DR5) Agonist

Overview of attention for article published in Molecular Cancer Therapeutics, November 2012

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (85th percentile)
Good Attention Score compared to outputs of the same age and source (74th percentile)

Mentioned by

twitter: 13 X users

patent: 1 patent

Readers on

mendeley: 47 Mendeley

So far, Altmetric has seen 23 X posts from 13 X users, with an upper bound of 118,949 followers.

RT @VivekSubbiah: In 2012 we published --> Targeting the Apoptotic Pathway in Chondrosarcoma Using Recombinant Human Apo2L/TRAIL (Dulanermi…

In 2012 we published --> Targeting the Apoptotic Pathway in Chondrosarcoma Using Recombinant Human Apo2L/TRAIL (Dulanermin), a Dual Proapoptotic Receptor (DR4/DR5) Agonist @MCT_AACR @OncoAlert @weldeiry @JTrentMDPhD @Dr_R_Kurzrock https://t.co/AGxzQ…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 19 additional X posts.